Tempus AI (NASDAQ:TEM) Stock Price Breaks Below 200-Day Moving Average on Insider Selling

Tempus AI logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Tempus AI shares fell below their 200-day moving average of $57.55, trading as low as $53.26 and last quoted at $53.98.
  • The CEO, CFO, and chief accounting officer sold shares; SEC filings say the transactions were to cover tax withholding on vested equity awards.
  • Analysts’ consensus rating is Hold, with an average price target of $79.37. In its latest quarter, Tempus beat EPS and revenue estimates, with revenue up 23.1% year over year.
  • Five stocks we like better than Tempus AI.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday after an insider sold shares in the company. The stock has a 200-day moving average of $57.55 and traded as low as $53.26. Tempus AI shares last traded at $53.9760, with a volume of 7,412,144 shares trading hands.

Specifically, CAO Ryan Bartolucci sold 1,540 shares of the firm's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $97,050.80. Following the completion of the sale, the chief accounting officer owned 59,264 shares of the company's stock, valued at $3,734,817.28. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 10,247 shares of the company's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $645,765.94. Following the completion of the transaction, the chief executive officer directly owned 652,216 shares in the company, valued at approximately $41,102,652.32. The trade was a 1.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In other news, CFO James Rogers sold 7,079 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total transaction of $446,118.58. Following the transaction, the chief financial officer owned 98,945 shares in the company, valued at approximately $6,235,513.90. This trade represents a 6.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TEM. Jefferies Financial Group raised Tempus AI from an "underperform" rating to a "hold" rating and raised their target price for the company from $35.00 to $70.00 in a report on Tuesday, November 3rd. Piper Sandler upgraded Tempus AI from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $56.00 to $76.00 in a report on Tuesday, September 1st. Weiss Ratings raised shares of Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, October 13th. JPMorgan Chase & Co. raised their price target on shares of Tempus AI from $45.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $85.00 price objective on shares of Tempus AI in a research report on Thursday. Eleven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $79.37.

View Our Latest Stock Report on Tempus AI

More Tempus AI News

These are some of the TEM news items that stood out recently:

  • Positive Sentiment: Tempus plans to present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium, which could increase visibility for its research and precision-medicine platform. Tempus to present 16 abstracts
  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating
  • Neutral Sentiment: Several senior executives, including the CEO and CFO, sold shares. The filings say the sales covered tax withholding obligations on vested equity awards, making them less indicative of a change in confidence, though multiple insider sales may still draw investor attention. Insider sale report

Tempus AI Stock Performance

The company has a market capitalization of $9.85 billion, a P/E ratio of -50.92 and a beta of 3.61. The firm has a 50 day moving average price of $72.79 and a two-hundred day moving average price of $57.55. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. During the same quarter last year, the company earned ($0.46) EPS. Tempus AI's revenue was up 23.1% on a year-over-year basis. On average, research analysts expect that Tempus AI, Inc. will post -1.20 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $27,000. EMC Capital Management bought a new position in shares of Tempus AI during the 2nd quarter valued at about $29,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $33,000. Ulland Investment Advisors LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $41,000. Finally, Heritage Family Offices LLP bought a new stake in Tempus AI during the 3rd quarter worth approximately $45,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines